Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising UpsideSeeking Alpha • 12/31/20
HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters' OptionGlobeNewsWire • 12/11/20
HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Preferred StockGlobeNewsWire • 12/09/20
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferred StockGlobeNewsWire • 12/08/20
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable TolerabilityGlobeNewsWire • 12/07/20
HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101GlobeNewsWire • 11/30/20
HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/12/20
HOOKIPA Pharma To Report Third Quarter 2020 Financial Results on November 12, 2020GlobeNewsWire • 11/03/20
HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed ArticleGlobeNewsWire • 09/16/20
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/13/20
HOOKIPA Pharma Reports Second Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/13/20
HOOKIPA Pharma Inc. (HOOK) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 08/06/20
HOOKIPA Pharma To Report Second Quarter 2020 Financial Results on August 13, 2020GlobeNewsWire • 08/04/20
HOOKIPA Pharma Inc. (HOOK) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/03/20
HOOKIPA Announces Positive Phase 2 Interim Safety and Immunogenicity Results for its CMV Vaccine Candidate HB‑101GlobeNewsWire • 06/22/20
HOOKIPA Announces Changes to its Board of Directors – Resignation of Sander van DeventerGlobeNewsWire • 06/19/20
HOOKIPA Announces FDA Clearance of its IND Application for HB-202/201 Clinical Trial to Treat HPV-Positive CancersGlobeNewsWire • 06/17/20
HOOKIPA Pharma Inc (HOOK) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/14/20